Back to Search
Start Over
Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial
- Source :
- Pharmacological Research, Vol 198, Iss , Pp 106991- (2023)
- Publication Year :
- 2023
- Publisher :
- Elsevier, 2023.
-
Abstract
- Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we investigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62) or placebo (n = 58) for 7 days. The primary outcomes were immune-related indicators. Subsequently, patients were stratified into two subgroups (CD4 < 38.25% and CD8 < 25.195%). Ninety-nine participants were analyzed: 47 and 52 in the carrimycin and placebo groups, respectively. HLA-DR levels were rapidly increased in the carrimycin group; however, the placebo group initially experienced a decline in HLA-DR level at 1 day after administration. In the subgroup with CD4
- Subjects :
- Carrimycin
CD8+ T cells
HLA-DR
Immune
Sepsis
Tumor
Therapeutics. Pharmacology
RM1-950
Subjects
Details
- Language :
- English
- ISSN :
- 10961186
- Volume :
- 198
- Issue :
- 106991-
- Database :
- Directory of Open Access Journals
- Journal :
- Pharmacological Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f2252d7e316045279d46a36620a91458
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.phrs.2023.106991